The difference between an out-of-specification (OOS) result and an out-of-trend (OOT) result in pharma, where OOT guidance comes from when no FDA regulation defines it, the Phase I and Phase II investigation in FDA's OOS guidance with its retesting, resampling, averaging and outlier rules, how an OOS result feeds CAPA under 21 CFR 211.192, and what FDA cited at 1,525 drug inspections that recorded an OOS-related citation between October 2008 and September 2026.